0.304

5.52% 0.0159

After Hours: .31 0.006 +1.97%

Cara Therapeutics Inc (CARA)

Overview News Price History Option Chain Financials Why CARA Down? Discussions Forecast Stock Split

Cara Therapeutics Inc stock is traded at $0.304, with a volume of 108.41K. It is up +5.52% in the last 24 hours and up +13.90% over the past month. Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Previous Close:

$0.2881

Open:

$0.286

24h Volume:

108.41K

Relative Volume:

0.22

Market Cap:

$16.68M

Revenue:

$20.97M

Net Income/Loss:

$-118.51M

P/E Ratio:

-0.1476

EPS:

-2.06

Net Cash Flow:

$-94.45M

1W Performance:

-0.36%

1M Performance:

+13.90%

6M Performance:

-50.72%

1Y Performance:

-68.28%

1-Day Range:

$0.286

$0.306

1-Week Range:

$0.285

$0.3187

52-Week Range:

$0.24

$1.31

Cara Therapeutics Inc Stock (CARA) Company Profile

Name

Cara Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

203-406-3700

Address

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CARA's Discussions on Twitter

Compare CARA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CARA Cara Therapeutics Inc	0.304	16.68M	20.97M	-118.51M	-94.45M	-2.19
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-13-24	Downgrade	Canaccord Genuity	Buy → Hold
Jun-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-13-24	Downgrade	Needham	Buy → Hold
Jun-13-24	Downgrade	Stifel	Buy → Hold
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jun-30-17	Downgrade	Janney	Buy → Neutral
Jun-30-17	Reiterated	Laidlaw	Buy
Jun-30-17	Reiterated	Stifel	Buy
Mar-28-17	Reiterated	H.C. Wainwright	Buy
Mar-28-17	Reiterated	Laidlaw	Buy
Mar-10-17	Reiterated	Laidlaw	Buy
Oct-13-16	Initiated	H.C. Wainwright	Buy
Aug-08-16	Reiterated	Needham	Buy

View All

Cara Therapeutics Inc Stock (CARA) Latest News

Nov 22, 2024

Cara Therapeutics IncReceives Non-Compliance Notice From Nasdaq On Minimum Stockholders’ Equity Requirement - XM

Nov 22, 2024

Nov 17, 2024

Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91% - Hartford Business Journal

Nov 15, 2024